TUMAGNOSTIC – Three key academic publications on CP-506
Several academic centers have collaborated with Convert Pharmaceuticals to expand knowledge about its main compound, CP-506, and the biomarkers that will enable selection of patients that would most benefit from the hypoxia activated prodrug under investigation. These research efforts have recently led to three key......